RecruitingPhase 3NCT07029217

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

A Prospective Phase III Study Comparing Standard Radiotherapy (24 Gy) With a PET REsponse-guided Very Low Dose (4 Gy) Staged Radiotherapy Strategy for Potentially Curable, Indolent B-cell Lymphomas


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

375 participants

Start Date

Jun 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT works against cancer in the area that is currently affected by cancer and if the therapy prevents new spots of lymphoma from developing. The researchers will also compare VLDRT with the standard dose of radiation therapy to see if VLDRT causes fewer side effects. Radiation therapy uses beams of intense energy to kill cancer cells. Standard doses of radiation therapy can cause short- and long-term side effects. Researchers think VLDRT may be as effective as standard doses, and, because VLDRT uses less radiation, researchers think VLDRT may cause fewer side effects than standard doses.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether lower doses of radiation therapy (compared to standard doses) are just as effective for people with slow-growing B-cell lymphomas (such as follicular lymphoma or marginal zone lymphoma). **You may be eligible if:** - You have been diagnosed with follicular lymphoma or marginal zone lymphoma (including subtypes recognized under current classification systems) - You have a measurable area of lymphoma that can be treated with radiation - You have previously received some form of treatment, or this is being considered as palliative (symptom-relieving) treatment **You may NOT be eligible if:** - You have an aggressive (fast-growing) type of lymphoma - You are pregnant - You have had prior radiation to the area being treated that has reached the maximum safe dose - You have active autoimmune disease requiring treatment with immune-suppressing medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiation (Standard)

24 Gy in 12 fractions

RADIATIONRadiation (Very low dose)

4 Gy in 1-2 consecutive daily fractions


Locations(7)

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)

Commack, New York, United States

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07029217


Related Trials